The clinical respiratory journal
-
Randomized Controlled Trial
Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24-h activity. FF is in development as a once-daily treatment for asthma as monotherapy and in combination with vilanterol (VI), a long-acting β2 agonist. Corticosteroids can have systemic effects on hypothalamic-pituitary-adrenal (HPA) axis function, potentially resulting in cortisol suppression. ⋯ FF/VI was found to be non-inferior to placebo on HPA axis function, with no indication of significant cortisol suppression after 42 days.
-
Randomized Controlled Trial
Acetazolamide improves oxygenation in patients with respiratory failure and metabolic alkalosis.
Coexistent respiratory failure and metabolic alkalosis is a common finding. Acidotic diuretics cause a fall in pH that may stimulate respiration. ⋯ Acetazolamide may constitute a useful adjuvant treatment mainly to be considered in selected patients with respiratory failure combined with prominent metabolic alkalosis or where non-invasive ventilation is insufficient or infeasible.
-
Randomized Controlled Trial
Training on a new, portable, simple simulator transfers to performance of complex bronchoscopy procedures.
Virtual-reality (VR) simulation provides a safe and effective learning environment prior to practicing on patients. However, existing bronchoscopy simulators are expensive and not easily portable. ⋯ The effect of a brief, self-directed training session using a portable, simple simulator was substantial and transferred to performance of more complex skills.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
GSK233705 is a recently developed inhaled anticholinergic being investigated for the potential treatment of chronic obstructive pulmonary disease (COPD). ⋯ All doses of GSK233705 demonstrated bronchodilatory activity and were well tolerated. Although the onset of bronchodilation was rapid, it was not sustained over 24 h making it unsuitable for once-daily dosing.